abstract

• Moxetumomab pasudotox is a second-generation recombinant immunotoxin against CD22 on B-cell lineages. Antileukemic activity has been demonstrated in children with chemotherapy-refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), with variable responses. Here, we report in vitro and in vivo evaluation of moxetumomab pasudotox treatment of human cell lines and patient-derived cells as a preliminary study to understand characteristics of sensitivity to treatment. Binding, internalization, and apoptosis were evaluated using fluorescently tagged moxetumomab pasudotox. Studies in NOD-scid IL2Rgnull mice showed a modest survival benefit in mice engrafted with 697 cells but not in NALM6 or the two patient-derived xenograft models.© 2017 Wiley Periodicals, Inc.

authors

• Barry, Patricia
• Chen, Jiayu
• Kinjyo, Ichiko
• Matlawska-Wasowska, Ksenia
• Matlawska-Wasowska, Ksenia
• Monks, Noel R
• Stuart S. Winter, MD
• Wilson, Bridget S

publication date

• November 2017
• January 1, 2017

published in

• Pediatric blood & cancer  Journal

keywords

• Adolescent
• Adult
• Animals
• Antineoplastic Agents
• Apoptosis
• Bacterial Toxins
• Cell Proliferation
• Child
• Child, Preschool
• Exotoxins
• Humans
• Male
• Mice
• Mice, Inbred NOD
• Mice, SCID
• Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
• Sialic Acid Binding Ig-like Lectin 2
• Tumor Cells, Cultured
• Xenograft Model Antitumor Assays
• Young Adult

Digital Object Identifier (DOI)

• https://doi.org/10.1002/pbc.26604

PubMed ID

• 28449314

start page

end page

volume

• 64

number

• 11